The present invention relates to the use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase includes the additive and an active agent dissolved therein. The additive has a higher affinity to water than to the active agent and controls the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate being proportional to the amount of active agent in the biphasic layer.

New metered-dosing compositions and methods of use comprising at least one psychedelic compound derived from living organisms such as plants and fungi, synthetically-derived forms or synthetic analogue. The composition for use in metered-dosing administration modalities, including a nasal spray, pressurized metered-dose inhaler, etc.

The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and characterized by a considerably increased utilization of the active substance.

The invention relates to a monopolymer multifunctional sequenced cast polyurethane matrix produced simply and efficiently, by sequentially pouring various isocyanate/polyol complex phase solutions successively into a mould with alternating solidification of said phase solutions according to a defined order and respecting the polymerisation stage (after the pot life and before the demolding time) of the sequence preceding the one being cast, so as to end with the casting of the last phase solution that will go up to the demolding time thereof and thereby finish the polymerisation of the whole of the matrix. It is loaded, in its “reservoir” sequences, with naturally originating or synthesised transdermally penetrating or volatile active substances. They are medicating and therapeutic, cosmetic, phytosanitary or wellness substances, repellents, attractants, pheromones, biocides, perfumes or deodorants. At least two active substances can be loaded into the same matrix in order to act unidirectionally or in opposite directions. Said matrix is used to form different devices that adhere to the skin or any other surface, in order to deliver at least one substance in a controlled manner. Said devices are patches, patches with a plurality of active substances, replaceable plasters stuck to a textile support, active heel pads and ball pads for shoes, pheromone cards for controlling insects, self-adhesive insecticide attractant cards, or other devices equivalent in terms of structure and function.

An applicator-based transdermal drug delivery system (ABTDS) for administration of drugs to a patient to treat ailments in combination with a wide range of topical formulation classes including but not limited to creams, foams, gels, lotions, and ointments is described herein. The transdermal drug delivery system utilizes an applicator that can be in various disk-like shapes and sizes, and that contain the topical formulation in a fixed area, and is applied over the skin of the patient to ensure accurate drug delivery and protect the drug from being rubbed away. Additional features of the applicator include numerous blunt spikes present on its surface that are designed to enhance rate of drug delivery.

A transdermal therapeutic system for administering at least one active pharmaceutical ingredient, including a polymer-based layer which is remote from the skin with a rate of application of at least 80 g/m.sup.2, and an adhesive skin-contact layer which is adjacent to the polymer-based layer remote from the skin and is based on acrylate copolymers with a rate of application of not more than 50 g/m.sup.2. The at least one active pharmaceutical ingredient is present in both the polymer-based layer remote from the skin and the skin-contact layer.

The present disclosure provides a patch preparation having features that prevent misuse. In some embodiments, a patch preparation containing a plaster on a support, wherein the plaster comprises a solvent having a vapor pressure equal to or greater than 1 kPa at 20° C. The patch preparation can lose its adhesion after the plaster is exposed to air and at least some of the solvent has evaporated, or if the patch is removed from the skin. This feature prevent the used patch from being applied to the skin again, and can prevent misuse. A method of forming a patch preparation is also disclosed.

An abuse deterrent and misuse deterrent transdermal patch comprising aversive agents incorporated in the backing layer of the patch. The aversive agents can exhibit biphasic or sustained kinetics of release with an immediate portion released rapidly and an extended portion released in a prolonged manner when exposed to a dissolution medium. The prolonged aversive agent release provides deterrence against extraction of drug from fresh and used patches and serves to prevent accidental misuse of used patches by children. The abuse deterrent and misuse deterrent patch systems can be used for transdermal delivery of therapeutically active agents and particularly those drugs that are highly prone to abuse such as opiate and opioid analgesics and stimulants.

Disclosed is a patch containing a plaster having fentanyl, an adhesive, a volatile hydrocarbon solvent (A), and a heteroatom-containing volatile organic solvent (B).

Unit dosage forms, devices, and kits for topical delivery of topical immunosensitizers are provided. These include dermal patches, glass swabs, and kits containing a dermal patch and a glass swab. Among other advantages, the unit dosage forms, devices, and kits presented herein deliver a more consistent and controlled volume of drug solution, prevent underdosing and overdosing, prevent or discourage repeat dosing, and provide a more consistent skin area to which the drug solution is applied.